S. Gracheck

发表

Bacterial two-component signalling as a therapeutic target in drug design. Inhibition of NRII by the diphenolic methanes (bisphenols).

J. Domagala, M. Cummings, D. Alessi, 1998, Advances in experimental medicine and biology.

5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.

G. Zeikus, E. Lunney, S. Gulnik, 2000, Journal of medicinal chemistry.

Genetic relationship between soxRS and mar loci in promoting multiple antibiotic resistance in Escherichia coli

S. Gracheck, P. Miller, M. Sulavik, 1994, Antimicrobial Agents and Chemotherapy.

Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.

G. Zeikus, C. Humblet, E. Lunney, 1999, Bioorganic & medicinal chemistry.

Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.

J. Domagala, S. Gracheck, M. Shapiro, 1996, Journal of medicinal chemistry.

In Vitro and In Vivo Activities of PD 0305970 and PD 0326448, New Bacterial Gyrase/Topoisomerase Inhibitors with Potent Antibacterial Activities versus Multidrug-Resistant Gram-Positive and Fastidious Organism Groups

S. Gracheck, M. Huband, E. Ellsworth, 2007, Antimicrobial Agents and Chemotherapy.

A new class of anti-HIV-1 agents targeted toward the nucleocapsid protein NCp7: the 2,2'-dithiobisbenzamides.

J. Domagala, D. Hupe, R. Schultz, 1997, Bioorganic & medicinal chemistry.

In vivo screen of genetically conserved Streptococcus pneumoniae proteins for protective immunogenicity.

S. Gracheck, N. Sheppard, J. Eyles, 2016, Vaccine.

2,2′-dithiobisbenzamides derived from α-, β- and γ-amino acids possessing anti-HIV activities: synthesis and structure–activity relationship

D. P. Mack, W. J. Turner, J. Domagala, 1998 .

Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity.

E. Lunney, S. Hagen, J. Domagala, 1997, Journal of medicinal chemistry.

3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.

J. Domagala, H. D. Showalter, J. Bronstein, 2006, Journal of medicinal chemistry.

Synthesis and structural-activity relationships of 3-hydroxyquinazoline-2,4-dione antibacterial agents.

J. Domagala, H. D. Showalter, S. Gracheck, 2004, Bioorganic & medicinal chemistry letters.

Synthesis and Antibacterial Activity of New Quinolones Containing a 7‐( 3‐(1‐Amino‐1‐methylethyl)‐1‐pyrrolidinyl) Moiety. Gram‐Positive Agents with Excellent Oral Activity and Low Side‐Effect Potential.

S. Hagen, J. Domagala, S. Gracheck, 1994 .

Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors.

J. Domagala, H. D. Showalter, S. Gracheck, 2007, Bioorganic & medicinal chemistry letters.

The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.

M. Cohen, J. Domagala, S. Gracheck, 1995, Journal of medicinal chemistry.

Synthesis and antibacterial activity of new quinolones containing a 7-[3-(1-amino-1-methylethyl)-1-pyrrolidinyl] moiety. Gram-positive agents with excellent oral activity and low side-effect potential.

S. Hagen, J. Domagala, S. Gracheck, 1994, Journal of medicinal chemistry.

Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.

J. Domagala, S. Gracheck, M. Shapiro, 1995, Journal of medicinal chemistry.

Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position

J. Domagala, R. Reynolds, S. Gracheck, 1996, Antimicrobial agents and chemotherapy.

Overexpression of the MarA positive regulator is sufficient to confer multiple antibiotic resistance in Escherichia coli

S. Gracheck, P. Miller, S J Gracheck, 1993, Journal of bacteriology.

In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.

M. Cohen, S. Yoder, S. Gracheck, 1997, The Journal of antimicrobial chemotherapy.

Chapter 17. Recent Developments in Cell Based Mechanism Screens

S. Gracheck, J. Marks, P. Miller, 1993 .

Limitations of the DNS assay for reducing sugars from saccharified lignocellulosics.

S. Gracheck, G. Emert, D. Rivers, 1984, Biotechnology and bioengineering.

Compounds That Target Novel Cellular Components Involved in HIV-1 Transcription

S. Gracheck, T. Folks, S. Butera, 1995, Molecular medicine.

Inhibition of the early phase of HIV replication by an isothiazolone, PD 161374.

J. Domagala, S. Gracheck, R. Gogliotti, 2001, Antiviral research.

Method for detecting gene expression of internalized Salmonella typhimurium in macrophages

S. Gracheck, S. Wold, 1994 .

Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl,5-methylphenyl thio) moiety: antiviral activities and pharmacokinetic properties.

E. Lunney, S. Hagen, J. Domagala, 1999, Bioorganic & medicinal chemistry letters.

Discovery and optimization of nonpeptide HIV-1 protease inhibitors.

E. Lunney, S. Hagen, J. Domagala, 1996, Bioorganic & medicinal chemistry.

4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.

C. Humblet, E. Lunney, S. Gulnik, 1997, Journal of medicinal chemistry.